@article{9eb789d277a946cabe2d3aad3778ee2e,
title = "Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines: Hematology",
author = "Shimon Slavin and Aliza Ackerstein and Lola Weiss and Arnon Nagler and Reuven Or and Elizabeth Naparstek",
note = "Funding Information: We wish to thank Dr. E. C. Franks, EuroCetus, Amsterdam, The Netherlands, for providing reoombinant IL-2 for experimental and clinical trials and Drs. M. I. Sherman and P. F. Sorter, Hoffmann LaRoche, Nutley, NJ, for providing recombinant human AID alFN for the murine studies. The authors thank the Israel Cancer Research Fund (Career Development Award to S. Slavin), and grants by the Ministry of Science and Technology, on behalf of the European Economic Community, and the US-Israel Binational Science Foundation (to S. Slavin) . The work was performed in the Max Moss Leukemia Research Laboratory, given in memory of her husband by Mrs. Adelaide Moss, England.",
year = "1992",
doi = "10.3109/07357909209032764",
language = "אנגלית",
volume = "10",
pages = "221--227",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",
}
